Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Associations Between Peritoneal Glucose Exposure, Glucose Degradation Product Exposure, and Peritoneal Membrane Transport Characteristics in Peritoneal Dialysis Patients: Secondary Analysis of the balANZ Trial.

Nataatmadja MS, Johnson DW, Pascoe EM, Darssan D, Hawley CM, Cho Y; balANZ Trial Investigators.

Perit Dial Int. 2018 Sep-Oct;38(5):349-355. doi: 10.3747/pdi.2017.00223. Epub 2018 Aug 7.

PMID:
30087174
2.

Association Between Peritoneal Glucose Exposure and Peritonitis in Peritoneal Dialysis Patients: The balANZ Trial.

Nataatmadja M, Cho Y, Pascoe EM, Darssan D, Hawley CM, Johnson DW; balANZ Trial Investigators.

Perit Dial Int. 2017 Jul-Aug;37(4):407-413. doi: 10.3747/pdi.2016.00263. Epub 2017 Apr 13. Erratum in: Perit Dial Int. 2017 Jul-Aug;37(4):486.

PMID:
28408714
3.

Predictors of Residual Renal Function Decline in Peritoneal Dialysis Patients: The balANZ Trial.

Htay H, Cho Y, Pascoe EM, Darssan D, Hawley C, Johnson DW; balANZ trial investigators.

Perit Dial Int. 2017 May-Jun;37(3):283-289. doi: 10.3747/pdi.2016.00206. Epub 2016 Dec 1.

PMID:
27935537
4.

Longitudinal Trend in Lipid Profile of Incident Peritoneal Dialysis Patients is Not Influenced by the Use of Biocompatible Solutions.

Cho Y, B├╝chel J, Steppan S, Passlick-Deetjen J, Hawley CM, Dimeski G, Clarke M, Johnson DW; balANZ Trial Investigators.

Perit Dial Int. 2016 Mar-Apr;36(2):146-53. doi: 10.3747/pdi.2014.00291. Epub 2015 Oct 1.

5.

Economic evaluation of neutral-pH, low-glucose degradation product peritoneal dialysis solutions compared with standard solutions: a secondary analysis of the balANZ Trial.

Howard K, Hayes A, Cho Y, Cass A, Clarke M, Johnson DW.

Am J Kidney Dis. 2015 May;65(5):773-9. doi: 10.1053/j.ajkd.2014.12.017. Epub 2015 Mar 4.

PMID:
25746151
6.

Higher Dialysate Matrix Metalloproteinase-2 Levels Are Associated with Peritoneal Membrane Dysfunction.

Cho Y, Johnson DW, Vesey DA, Hawley CM, Pascoe EM, Clarke M, Topley N; balANZ Trial Investigators.

Perit Dial Int. 2016 Jan-Feb;36(1):16-25. doi: 10.3747/pdi.2013.00274. Epub 2014 Oct 7.

7.

Baseline serum interleukin-6 predicts cardiovascular events in incident peritoneal dialysis patients.

Cho Y, Johnson DW, Vesey DA, Hawley CM, Pascoe EM, Clarke M, Topley N; balANZ Trial Investigators.

Perit Dial Int. 2015 Jan-Feb;35(1):35-42. doi: 10.3747/pdi.2013.00272. Epub 2014 Apr 7.

8.

Utility of Urinary Biomarkers in Predicting Loss of Residual Renal Function: The balANZ Trial.

Cho Y, Johnson DW, Vesey DA, Hawley CM, Clarke M, Topley N; balANZ Trial Investigators.

Perit Dial Int. 2015 Mar-Apr;35(2):159-71. doi: 10.3747/pdi.2013.00170. Epub 2014 Apr 7.

9.

Dialysate interleukin-6 predicts increasing peritoneal solute transport rate in incident peritoneal dialysis patients.

Cho Y, Johnson DW, Vesey DA, Hawley CM, Pascoe EM, Clarke M, Topley N; balANZ Trial Investigators.

BMC Nephrol. 2014 Jan 10;15:8. doi: 10.1186/1471-2369-15-8.

10.

Does the use of neutral pH, low glucose degradation product peritoneal dialysis fluids lead to better patient outcomes?

Cho Y, Johnson DW.

Curr Opin Nephrol Hypertens. 2014 Mar;23(2):192-7. doi: 10.1097/01.mnh.0000441046.13912.1f. Review.

PMID:
24378773
11.

What has balANZ taught us about balancing ultrafiltration with membrane preservation?

Davies SJ.

Nephrol Dial Transplant. 2013 Aug;28(8):1971-4. doi: 10.1093/ndt/gfs594. Epub 2013 May 9. No abstract available.

PMID:
23661690
12.

The effects of biocompatible compared with standard peritoneal dialysis solutions on peritonitis microbiology, treatment, and outcomes: the balANZ trial.

Johnson DW, Brown FG, Clarke M, Boudville N, Elias TJ, Foo MW, Jones B, Kulkarni H, Langham R, Ranganathan D, Schollum J, Suranyi MG, Tan SH, Voss D; balANZ Trial Investigators.

Perit Dial Int. 2012 Sep-Oct;32(5):497-506.

13.
14.

The effect of low glucose degradation product, neutral pH versus standard peritoneal dialysis solutions on peritoneal membrane function: the balANZ trial.

Johnson DW, Brown FG, Clarke M, Boudville N, Elias TJ, Foo MW, Jones B, Kulkarni H, Langham R, Ranganathan D, Schollum J, Suranyi MG, Tan SH, Voss D; balANZ Trial Investigators.

Nephrol Dial Transplant. 2012 Dec;27(12):4445-53. doi: 10.1093/ndt/gfs314. Epub 2012 Aug 1.

15.

Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes.

Johnson DW, Brown FG, Clarke M, Boudville N, Elias TJ, Foo MW, Jones B, Kulkarni H, Langham R, Ranganathan D, Schollum J, Suranyi M, Tan SH, Voss D; balANZ Trial Investigators.

J Am Soc Nephrol. 2012 Jun;23(6):1097-107. doi: 10.1681/ASN.2011121201. Epub 2012 Mar 22.

16.

Supplemental Content

Loading ...
Support Center